Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children
Authors:
- Soo-Han ChoiSCSoo-Han Choi
- Dong Hyun KimDKDong Hyun Kim
- Jong Gyun AhnJAJong Gyun Ahn
- Ki Wook YunKYKi Wook Yun
- Byung-Wook EunBEByung-Wook Eun
- Jina LeeJLJina Lee
- Taek-Jin LeeTLTaek-Jin Lee
- Hyunju LeeHLHyunju Lee
- Dae Sun JoDJDae Sun Jo
- Eun Young ChoECEun Young Cho
- Hye-Kyung ChoHCHye-Kyung Cho
- Young June ChoeYCYoung June Choe
Open Access
- 15 October 2025
- journal article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (10) , 742-750
Abstract
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent RSV-associated LRTI among infants and young children. Nirsevimab was launched in Korea in February 2025. This report summarizes the recommendations of the Committee on Infectious Diseases of the Korean Pediatric Society regarding the use of nirsevimab. We recommend a single dose of nirsevimab for all neonates born during the RSV season (October to March), as well as all infants younger than 6 months at the start of the RSV season (i.e., those born between April and September of that year). Nirsevimab should be administered shortly after birth (within the first week of life) to neonates born during the RSV season and just before or early in the season (late September to October) to infants entering their first RSV season. Nirsevimab may also be considered for children younger than 2 years of age who are at increased risk of severe RSV disease and entering their second RSV season.Keywords
This publication has 57 references indexed in Scilit:
- Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeThe Lancet Infectious Diseases, 2022
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsNew England Journal of Medicine, 2022
- Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or PrematurityNew England Journal of Medicine, 2022
- WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global useVaccine, 2022
- Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsNew England Journal of Medicine, 2020
- Respiratory syncytial virus entry and how to block itNature Reviews Microbiology, 2019
- Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approachesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusScience, 2013